NEUROHUMORAL IMBALANCE AS A CAUSE OF PROGRESSION OF CHRONIC HEART FAILURE

  • O.A. Osipova Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015
  • V.N. Fedorets Saint Petersburg State Pediatric Medical University. Lithuania 2, Saint Petersburg, Russian Federation, 194100
  • E.V. Gosteva Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015
  • A.S. Brizhaneva Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015 https://orcid.org/0009-0007-3640-652X
  • A.Yu. Ulyanova Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015
  • A.A. Kryshka Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015
  • A.V. Serdukova Belgorod State National Research University. Pobedy str., 85, Belgorod, Russian Federation, 308015
DOI: https://doi.org/10.56871/MTP.2024.25.47.007
Keywords: chronic heart failure, neurohumoral disbalance, neurohumoral mechanisms

Abstract

One of the main tasks of the cardiological medical community is to solve the problem of decompensation prevention and create a basis for stable treatment of chronic heart failure (CHF). However, previously performed studies in the Russian Federation were limited to one or more regions and had a small sample size (strict inclusion criteria were imposed) and had a short follow-up period. Available data on the treatment of outpatient patients with heart failure (HF), including low ejection fraction (EF) and HF with moderately reduced left ventricular LV, are few and contradictory. The activity of neurohumoral mechanisms plays a key role in the progression of HF. These mechanisms are important for the regulation of vasopressor and vasodilating processes in blood circulation and water-salt metabolism. The sympathoadrenal system, renin-angiotensin-aldosterone system, natriuretic system and endothelial mechanisms interact in a complex network, ensuring the normal functioning of the body. The purpose of this review is to analyze the mechanisms of development and progression of chronic heart failure. The analysis of available publications over the past 5 years has been carried out by keywords: “chronic heart failure”, “the mechanism” of development in Russianlanguage literature (elibrary) and English-language databases (PubMed, Scopus, Web of Science).

References

Виноградова Н.Г., Поляков Д.С., Фомин И.В. Анализ смертности у пациентов с ХСН после декомпенсации при длительном наблюдении в условиях специализированной медицинской помощи и в реальной клинической практике. Кардиология. 2020; 60(4): 91–100 https://doi.org/10.18087/cardio.2020.4.n1014

Осипова О.А., Гостева Е.В., Брижанева А.С. и др. Роль биомаркеров обмена коллагена и системного воспаления в ремоделировании миокарда у пациентов со стабильной хронической ишемической болезнью сердца и обструктивным апноэ сна. Кардио­васкулярная терапия и профилактика. 2023; 22(12): 20–7. DOI: 10.15829/1728-8800-2023-3819. EDN FPMMDJ

Осипова О.А., Гостева Е.В., Чефранова Ж.Ю. и др. Влияние фармакотерапии на динамику маркеров обмена коллагена у больных хронической сердечной недостаточностью с промежуточной фракцией выброса на фоне ишемической болезни сердца в старших возрастных группах. Кардиоваскулярная терапия и профилактика. 2020; 19(5): 26–51. DOI: 10.15829/17288800 2020 2651.

Полунина О.С., Воронина Л.П., Севостьянова И.В., Полунина Е.А. Клинико-прогностическое значение определения уровня неоптерина у больных хронической сердечной недостаточностью с сохранной фракцией выброса. Медицинский вестник Юга России. 2018; 9(3): 84–9. DOI: 10.21886/2219-8075-2018-9-3-84-89.

Поляков Д.С., Фомин И.В., Беленков Ю.Н. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА-ХСН. Кардиология. 2021; 61(4): 4–14. DOI: 10.18087/cardio.2021.4.n1628

Попов Е.А., Полунина Е.А., Воронина Л.П. и др. Анализ уровня маркеров воспаления у больных с хронической сердечной недостаточностью. Кардио­васкулярная терапия и профилактика. 2018; 17(5): 47–52. DOI: 10.15829/1728-8800-2018-5-47-52

Фомин И.В., Поляков Д.С., Вайсберг А.Р. 25 лет реальной клинической практики в лечении хронической сердечной недостаточности в РФ — все ли мы правильно делаем в 2022 году? Медицинский альманах. 2022; 4(73).

Шишкина В.В., Атякшин Д.А. Участие тучных клеток кожи в механизмах фибриллогенеза под влиянием невесомости. Морфология. 2019; 155(2): 328.

Anker S. D., Butler J., Filippatos G. et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451–61. DOI: 10.1056/NEJMoa2107038.

Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci. 2002; 115(Pt19): 3719–27. DOI: 10.1242/jcs.00063.

Buken C., Sahana J., Corydon T.J. et al. Morphological and Molecular Changes in Juvenile Normal Human Fibroblasts Exposed to Simulated Microgravity. Scientific Reports. 2019; 9(1): 11882. DOI: 10.1038/s41598-019-48378-9.

Hou J.Y., Wang X.N., Qiu G. et al. Correlation between CT small airway parameters, T-lymphocyte subsets and MMP-9 level in patients with bronchial asthma. J Biol Regul Homeost Agents. 2020; 34(6): 2299–2304. DOI: 10.23812/20-520-L.

Ibrahim N.E., Song Y., Cannon C.P. et al. Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry? ESC Heart Fail. 2019; 6: 784–92.

Lahdentausta L., Leskelä J., Winkelmann A. et al. Serum ММP 9 Diagnostics, Prognostics, and Activation in Acute Coronary Syndrome and Its Recurrence. Cardiovasc Transl Res. 2018; 11(3): 210–20. DOI: 10.1007/s12265-018-9789-x.

McDonagh T.A., Metra M., Adamo M., et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur JHeart Fail. 2022; 24(1): 4–131. DOI: 10.1002/ejhf.2333.

Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85(1): 1–31. DOI: 10.1152/physrev.00048.2003.

Persic V., Bastiancic A.L., Rosovic I. et al. Correlation between immunological inflammatory markers and endothelial disfunc tion in the early stage of coronary heart disease. Med Hypotheses. 2018; 115: 726. DOI: 10.1016/j.mehy.2018.04.001.

Rosano GMC., Seferovic P., Savarese G. et al. Impact analysis of heart failure across European countries: an ESC-HFA position paper. ESC Heart Fail. 2022; 9(5): 2767–78. DOI: 10.1002/ehf2.14076.

Solomon S. D., McMurray J.J.V., Anand I. S. et al. PARAGON-HF Investigators and Committees. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019; 381(17): 1609–20. DOI: 10.1056/NEJMoa1908655.

Solomon S. D., McMurray J.J.V., Claggett B. et al. DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12): 1089–98. DOI: 10.1056/NEJMoa2206286.

Woessner J.F. MMPs and TIMPs — an historical perspective. Mol Biotechnol. 2002; 22(1): 33–49. DOI: 10.1385/MB:22:1:033.

Published
2024-07-30
How to Cite
Osipova, O., Fedorets, V., Gosteva, E., Brizhaneva, A., Ulyanova, A., Kryshka, A., & Serdukova, A. (2024). NEUROHUMORAL IMBALANCE AS A CAUSE OF PROGRESSION OF CHRONIC HEART FAILURE. Medicine: Theory and Practice, 9(1), 62-68. https://doi.org/10.56871/MTP.2024.25.47.007
Issue
Vol 9 No 1 (2024)
Section
Статьи

Most read articles by the same author(s)